type 2 Diabetes (T2DM)
Conditions
Interventions
Control group:Metformine
Test group:Hengglizin 10 mg qd + Repagliptin 100 mg qd + metformin 500mg bid
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Untreated patients with primary T2DM; 2. Age >=18 years old; 3. 8.0%= 60 ml/min1.73m^2; 6. Voluntarily participate and sign informed consent;
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women and women of childbearing age who do not want to use reliable contraception; 2. People who are known to be allergic to hengglagliptin, repagliptin or metformin; 3. Other types of diabetes except type 2 diabetes; 4. Type 2 diabetes mellitus with a history of ketoacidosis (DKA) within the last 6 months; 5. NYHA heart grade IV; 6. Hospital admission for acute coronary syndrome (ST elevation myocardial infarction, non-ST elevation myocardial infarction, or unstable angina pectoris), percutaneous coronary intervention, or cardiac surgery within 30 days before the screening visit; Or plan to undergo percutaneous coronary intervention or heart surgery within 3 months. 7. Confirmed respiratory diseases (such as chronic obstructive pulmonary disease, pulmonary hypertension, etc.); 8. Previous acute or chronic pancreatitis; 9. Uncontrolled hypertension, defined as systolic blood pressure >=160 mmHg and/or diastolic blood pressure >=100 mmHg during the screening visit (the average of three blood pressure measurements in the supine position); 10. Patients with postural hypotension and/or systolic blood pressure <90 mmHg at visit 0 or visit 1, or who are considered hypovolemic by the clinician; 11. For patients with diagnosed malignant tumors, life expectancy is less than 1 year; 12. Patients with a history of repeated urinary and reproductive tract infections (clinician judgment); 13. Patients participating in other clinical trials within 3 months; 14. Addiction to alcohol or drugs. 15. In addition to the above, the investigators judged that the patients were not suitable to participate in this clinical trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;waistline;Seven point blood sugar;FBG(fasting blood-glucose);Fasting plasma C-peptide /FCP;fasting insulin FINS;2-hour C-peptide;2-hour insulin;liver function;renal function;blood lipid;UACR;blood routine examination;urinalysis; | — |
Countries
China
Contacts
Public ContactJunqing Zhang
Peking University First Hospital
Outcome results
None listed